Major depressive disorder, sleep EEG and agomelatine: an open-label study

Maria-Antonia Quera Salva, Bernard Vanier, Judith Laredo, Sarah Hartley, Florian Chapotot, Catherine Moulin, Frédéric Lofaso, Christian Guilleminault
2007 International Journal of Neuropsychopharmacology  
This open study evaluates the effect of agomelatine, a melatonergic receptor agonist and 5-HT 2C antagonist antidepressant, on sleep architecture in patients suffering from major depressive disorder. Fifteen outpatients with a baseline HAMD score o20 were treated with 25 mg/d agomelatine for 42 d. Polysomographic studies were performed at baseline, day 7, day 14, and day 42. Sleep efficiency, time awake after sleep onset and the total amount of slow-wave sleep (SWS) increased at week 6. The
more » ... at week 6. The increase of SWS was predominant during the first sleep cycle. The amount of SWS decreased throughout the first four sleep cycles from day 7 and delta ratio increased from day 14 onwards. No change in rapid eye movement (REM) latency, amount of REM or REM density was observed and agomelatine was well tolerated. In conclusion agomelatine improved sleep continuity and quality. It normalized the distribution of SWS sleep and delta power throughout the night.
doi:10.1017/s1461145707007754 pmid:17477886 fatcat:vzqbv3tsszhixoxxywhz3qhsmi